Omiloxetine

Omiloxetine is a norepinephrine reuptake inhibitor that was under development for the treatment of depression and anxiety disorders but was never marketed. It was developed by Eli Lilly and Company.

History

Omiloxetine was developed in the 1980s by Eli Lilly and Company, a pharmaceutical company based in the United States. The drug was intended to be a norepinephrine reuptake inhibitor, a type of drug that increases the amount of norepinephrine in the brain by preventing it from being reabsorbed into nerve cells. This type of drug is commonly used to treat conditions such as depression and anxiety disorders.

Despite initial promise, omiloxetine was never marketed. The reasons for this are not publicly known, but it is possible that the drug did not meet the necessary safety and efficacy standards in clinical trials.

Pharmacology

As a norepinephrine reuptake inhibitor, omiloxetine works by increasing the amount of norepinephrine in the brain. Norepinephrine is a neurotransmitter, a chemical that transmits signals in the brain. It is involved in regulating mood and anxiety.

By preventing norepinephrine from being reabsorbed into nerve cells, omiloxetine increases the amount of this neurotransmitter available in the brain. This can help to alleviate symptoms of depression and anxiety.

See also

• Norepinephrine reuptake inhibitor
• Depression
• Anxiety disorder
• Eli Lilly and Company

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia